These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 27637171)

  • 1. Use of a Target-Mediated Drug Disposition Model to Predict the Human Pharmacokinetics and Target Occupancy of GC1118, an Anti-epidermal Growth Factor Receptor Antibody.
    Park WS; Han S; Lee J; Hong T; Won J; Lim Y; Lee K; Byun HY; Yim DS
    Basic Clin Pharmacol Toxicol; 2017 Mar; 120(3):243-249. PubMed ID: 27637171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A target-mediated drug disposition population pharmacokinetic model of GC1118, a novel anti-EGFR antibody, in patients with solid tumors.
    Chung TK; Lee HA; Park SI; Oh DY; Lee KW; Kim JW; Kim JH; Woo A; Lee SJ; Bang YJ; Lee H
    Clin Transl Sci; 2021 May; 14(3):990-1001. PubMed ID: 33382918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose.
    Kamath AV; Lu D; Gupta P; Jin D; Xiang H; Wong A; Leddy C; Crocker L; Schaefer G; Sliwkowski MX; Damico-Beyer LA
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):1063-9. PubMed ID: 22203367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target-mediated drug disposition and prolonged liver accumulation of a novel humanized anti-CD81 monoclonal antibody in cynomolgus monkeys.
    Vexler V; Yu L; Pamulapati C; Garrido R; Grimm HP; Sriraman P; Bohini S; Schraeml M; Singh U; Brandt M; Ries S; Ma H; Klumpp K; Ji C
    MAbs; 2013; 5(5):776-86. PubMed ID: 23924796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
    Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors.
    Oh DY; Lee KW; Han SW; Kim JW; Shin JW; Jo SJ; Won J; Hahn S; Lee H; Kim WH; Bang YJ
    Oncologist; 2019 Aug; 24(8):1037-e636. PubMed ID: 31164456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of human pharmacokinetics of therapeutic monoclonal antibodies from simple allometry of monkey data.
    Oitate M; Masubuchi N; Ito T; Yabe Y; Karibe T; Aoki T; Murayama N; Kurihara A; Okudaira N; Izumi T
    Drug Metab Pharmacokinet; 2011; 26(4):423-30. PubMed ID: 21606605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer Patients.
    Lobet S; Paintaud G; Azzopardi N; Passot C; Caulet M; Chautard R; Desvignes C; Capitain O; Tougeron D; Lecomte T; Ternant D
    Clin Pharmacokinet; 2023 Sep; 62(9):1263-1274. PubMed ID: 37442917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition.
    Luu KT; Bergqvist S; Chen E; Hu-Lowe D; Kraynov E
    J Pharmacol Exp Ther; 2012 Jun; 341(3):702-8. PubMed ID: 22414855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice.
    Hurwitz SJ; Zhang H; Yun S; Batuwangala TD; Steward M; Holmes SD; Rycroft D; Pan L; Tighiouart M; Shin HJ; Koenig L; Wang Y; Chen ZG; Shin DM
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):577-90. PubMed ID: 21913035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?
    Deng R; Iyer S; Theil FP; Mortensen DL; Fielder PJ; Prabhu S
    MAbs; 2011; 3(1):61-6. PubMed ID: 20962582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Target-mediated drug disposition modeling of an anti-TFPI antibody (MG1113) in cynomolgus monkeys to predict human pharmacokinetics and pharmacodynamics.
    Kwak EY; Kim MJ; Park JH; Jung HW; Jung ME
    J Thromb Haemost; 2021 Jun; 19(6):1425-1435. PubMed ID: 33448093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of Human Pharmacokinetics of Antibody-Drug Conjugates From Nonclinical Data.
    Li C; Zhang C; Deng R; Leipold D; Li D; Latifi B; Gao Y; Zhang C; Li Z; Miles D; Chen SC; Samineni D; Wang B; Agarwal P; Lu D; Prabhu S; Girish S; Kamath AV
    Clin Transl Sci; 2019 Sep; 12(5):534-544. PubMed ID: 31115997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis.
    Betts AM; Clark TH; Yang J; Treadway JL; Li M; Giovanelli MA; Abdiche Y; Stone DM; Paralkar VM
    J Pharmacol Exp Ther; 2010 Apr; 333(1):2-13. PubMed ID: 20089807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
    Glassman PM; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma.
    Kamath AV; Lu D; Gupta P; Jin D; Xin Y; Brady A; Stephan JP; Li H; Tien J; Qing J; Damico-Beyer LA
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):1071-8. PubMed ID: 22203368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanistic investigation of the preclinical pharmacokinetics and interspecies scaling of PF-05231023, a fibroblast growth factor 21-antibody protein conjugate.
    Giragossian C; Vage C; Li J; Pelletier K; Piché-Nicholas N; Rajadhyaksha M; Liras J; Logan A; Calle RA; Weng Y
    Drug Metab Dispos; 2015 Jun; 43(6):803-11. PubMed ID: 25805881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Semimechanistic model to characterize nonlinear pharmacokinetics of nimotuzumab in patients with advanced breast cancer.
    Rodríguez-Vera L; Ramos-Suzarte M; Fernández-Sánchez E; Soriano JL; Guitart CP; Hernández GC; Jacobo-Cabral CO; de Castro Suárez N; Codina HC
    J Clin Pharmacol; 2015 Aug; 55(8):888-98. PubMed ID: 25760761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose.
    de Vries Schultink AHM; Doornbos RP; Bakker ABH; Bol K; Throsby M; Geuijen C; Maussang D; Schellens JHM; Beijnen JH; Huitema ADR
    Invest New Drugs; 2018 Dec; 36(6):1006-1015. PubMed ID: 29728897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective analysis of model-based predictivity of human pharmacokinetics for anti-IL-36R monoclonal antibody MAB92 using a rat anti-mouse IL-36R monoclonal antibody and RNA expression data (FANTOM5).
    Ahlberg J; Giragossian C; Li H; Myzithras M; Raymond E; Caviness G; Grimaldi C; Brown SE; Perez R; Yang D; Kroe-Barrett R; Joseph D; Pamulapati C; Coble K; Ruus P; Woska JR; Ganesan R; Hansel S; Mbow ML
    MAbs; 2019 Jul; 11(5):956-964. PubMed ID: 31068073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.